CinCor Pharma

CinCor Pharma, Inc. operates as a clinical-stage biopharmaceutical company focused on developing its clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. The firm is developing CIN-107 for the treatment of multiple diseases where aldosterone plays a significant role in disease pathophysiology, including hypertension and primary aldosteronism, as well as its utility in ameliorating complications of chronic kidney disease. The company was founded by Jon Isaacsohn and Catherine Pearce on March 28, 2018 and is headquartered in Waltham, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

WALTHAM, Mass., April 19, 2022 (GLOBE NEWSWIRE) --  CinCor Pharma, Inc. (“CinCor”) today announced its participation in the Jefferies Biotech on the Bay Summit taking place April 26-27 in Miami, Florida.

CinCor Pharma to Participate in Jefferies Biotech on the Bay Summit

BrigHtn Phase 2 study with CIN-107 for Resistant Hypertension Enrollment Complete with Topline Results Expected in 2H 2022

CinCor Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update

BOSTON, March 17, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases, today announced that the Company will be added to the Russell 2000® and Russell 3000® Indexes, effective on Friday, March 18, 2022, as part of the quarterly initial public offering (IPO) additions.

CinCor Pharma to be Added to Russell 2000® and Russell 3000® Indexes

BOSTON, March 15, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases, today announced that it will report its fourth quarter and full year 2021 financial results before the open of the U.S. financial markets on Tuesday, March 22, 2022. Following the announcement, the Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

CinCor Pharma to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on March 22, 2022

BOSTON, March 03, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases, today announced that its management team will present at the 32nd Annual Oppenheimer Healthcare Conference taking place March 15-17, 2022.

CinCor Pharma to Present at the 32nd Annual Oppenheimer Healthcare Conference

Amylyx Pharmaceuticals

Vigil Neuroscience

Should you add these stocks to your portfolio?

New Year, Fresh Stocks: 3 IPOs That Joined the Market in January

BOSTON, Jan. 13, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced the appointment of the independent member June Lee, M.D. to the company's Board of Directors. Dr. Lee brings decades of leadership experience in the biotechnology and pharmaceutical industry and has served in numerous executive and board roles.

CinCor Pharma Appoints June Lee to Its Board of Directors

Alarm.com

Amazon

ASML Hld

Alphabet

Intuit

Lucid Group

NVIDIA

Smith & Wesson Brands

Vroom

With the technology-centric Nasdaq having a rough time of things, this sets up possible attractive discounts for stocks to buy. The post 10 Best Stocks to Buy on the Nasdaq Right Now appeared first on InvestorPlace.

10 Best Stocks to Buy on the Nasdaq Right Now

Hour Loop

The IPO market kicked off the new year with three biotechs and an online home goods retailer, joined by four SPACs. Four SPACs went public led by Sagansky and Sloan's Screaming Eagle Acquisition, which raised $750 million.

U.S. IPO Weekly Recap: Biotechs Ring In The New Year In A 4 IPO Week

Amylyx Pharmaceuticals raised $190 million, CinCor Pharma collected nearly $194 million, and Vigil Neuroscience came in at $98 million.

The Year's First Three IPOs All Went 'Clunk.' This Is Why.

Three Biotech IPOs Started Trading. Here's How the Stocks Did.

CinCor Pharma Inc.'s stock CINC, +0.22% shot out of the gate in morning trading Friday, but then pulled back sharply, to trade briefly below in negative territory. The Massachusetts-based biopharmaceutical company's stock's first trade was at $21.00 at 11:05 a.m.

CinCor Pharma's stock opens well above IPO price, then sells off sharply

CinCor Pharma Inc. CINC, is set to go public on the Nasdaq Friday, after the Massachusetts-based biopharmaceutical company's upsized initial public offering priced overnight at $16 a share, in the middle of the expected range of between $15 and $17 a share. The company raised $193.6 million as it sold 12.1 million shares in the IPO, up from previous expectations of an 11.0 million share offering.

CinCor Pharma raised $194 million as upsized IPO prices in middle of expected range

BOSTON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) (Nasdaq: CINC), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases, today announced the pricing of its initial public offering of 12,100,000 shares of common stock at a price to the public of $16.00 per share. The gross proceeds to CinCor from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $193.6 million. All of the shares are being offered by CinCor. In addition, CinCor has granted the underwriters a 30-day option to purchase up to an additional 1,815,000 shares of its common stock at the initial public offering price less the underwriting discounts and commissions.

CinCor Pharma Announces Pricing of Initial Public Offering

Three biotechs launched their offerings on Monday, set to be the first IPOs of the new year. Amylyx is developing oral small molecule therapies for amyotrophic lateral sclerosis and a broad range of neurodegenerative diseases.

2022 IPO Market Kicks Off With 3 Biotechs Set To Trade On Friday

CinCor Pharma Inc. CINC, +0.73% has set terms for its initial public offering, in which the Massachusetts-based biopharmaceutical company focusing on treatments of hypertension, could be valued at up to $602.1 million. The company could raise up to $187.0 million, as it is offering 11.0 million shares in the IPO, which is expected to price between $15 and $17 a share.

CinCor Pharma sets IPO terms, as the biotech looks to raise up to $187 million

BOSTON, Jan. 03, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases, today announced that it has launched an initial public offering of 11,000,000 shares of its common stock pursuant to a registration statement on Form S-1 filed with the Securities and Exchange Commission. The initial public offering price is expected to be between $15 and $17 per share. All shares of common stock to be sold in the proposed offering will be offered by CinCor. CinCor also intends to grant the underwriters a 30-day option to purchase up to an additional 1,650,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. CinCor's common stock is expected to begin trading on the Nasdaq Global Market under the symbol “CINC.”

CinCor Pharma Launches Roadshow for Proposed Initial Public Offering of Common Stock

News for CinCor Pharma Stock (CINC)